REGENXBIO Inc.

NASDAQ:RGNX

Biotechnology

Healthcare
$7.26 +1.97%

+$0.16 today

Market cap
$480.05M
Beta
1.03
P/E (TTM)
-1.5
EPS (TTM)
-$5.53
52W Low $5.46High $16.19

Volume 0.70M

Average 1.24M

RGNX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

REGENXBIO Inc.NASDAQ: RGNX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to -73.2%

Gross margin was -73.2% in Q1 FY2026, down 169.4 pp from a year earlier. On a trailing-twelve-month basis it was -0.1%, down 76.7 pp year over year. Over 3 fiscal years it widened by 36.5 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-73.2%-153.7 pp QoQ
Last fiscal yearDec 2025
88.1%+28.4 pp YoY
LTMMar 2026
-0.1%-76.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-169.4 pp——
1 year+28.4 pp——
3 years+36.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
88.1%
Year-over-year change
+28.4pp

Gross Margin vs competitors

How RGNX compares with its peers on the latest reported figures

  • RGNX's LTM Mar 2026 gross margin of -0.1% is the 5th highest of the 7 companies compared; the peer median is 81.9%.
  • Its year-over-year change of -76.7 pp is the lowest of 7, against a peer median of +42.4 pp.
  • Over three fiscal years its change of +36.5 pp compares with a peer median of -6.6 pp.
RGNX Competitors Peer median
Gross Margin for RGNX and competitors
Company Period LTM level YoY 3-year change
OCGNOcugen, Inc.LTM Mar 2026100.0% +0.0 pp-54.1 pp
MGTXMeiraGTx Holdings plcLTM Mar 202691.6% +64.6 pp-6.0 pp
PGENPrecigen, Inc.LTM Jun 202689.6% +108.3 pp-39.4 pp
QUREuniQure N.V.LTM Mar 202674.1% +20.2 pp-7.3 pp
RGNXREGENXBIO Inc.LTM Mar 2026-0.1% -76.7 pp+36.5 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-12.4% +490439.7 pp+2555.9 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-86.7% +2.3 pp+136.3 pp
SLDBSolid Biosciences Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
LXEOLexeo Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding RGNX) 81.9%+42.4 pp-6.6 pp

Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue470.35M112.72M90.24M83.33M170.44M
Cost of Revenue51.83M54.55M37.21M33.57M20.3M
Gross Profit418.51M58.18M53.03M49.76M150.14M
Gross Margin89.0%51.6%58.8%59.7%88.1%
Research & Development181.44M242.45M232.27M208.52M228.3M
Selling, General & Admin79.33M85.28M88.49M76.62M82.86M
Operating Expenses258.53M321.06M321.16M283.11M311.34M
Depreciation & Amortization9.56M12.91M17.32M16.22M15.62M
EBITDA177.09M(244.24M)(239.46M)(198.23M)(133.26M)
EBITDA Margin37.7%-216.7%-265.4%-237.9%-78.2%
Operating Income159.98M(262.88M)(268.13M)(233.35M)(161.2M)
Operating Margin34.0%-233.2%-297.1%-280.0%-94.6%
Interest Income719K342K25K174K12.27M
Interest Expense26.28M23.25M6.86M12.66M45.01M
Other Income / Expenses(18.73M)(17.53M)4.48M6.24M(32.68M)
Income Before Tax141.25M(280.41M)(263.65M)(227.1M)(193.88M)
Pre-Tax Margin30.0%-248.8%-292.2%-272.5%-113.8%
Income Tax Expense13.41M(84K)(152K)00
Net Income127.84M(280.32M)(263.49M)(227.1M)(193.88M)
Net Margin27.2%-248.7%-292.0%-272.5%-113.8%
EPS (Basic)3.01(6.50)(6.02)(4.59)(3.76)
EPS (Diluted)2.91(6.50)(6.02)(4.59)(3.76)
Weighted Avg Shares42.44M43.15M43.73M49.51M51.57M
Weighted Avg Shares (Diluted)43.91M43.15M43.73M49.51M51.57M

REGENXBIO Inc.

NASDAQ:RGNX

Intrinsic Alpha fair value

Locked

Current Price

$7.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.